Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study (NSABP P-1)

The adage ‘Prevention is better than cure’ has been adopted as a fundamental principle in modern health care worldwide, and is inherent in strategies to reduce disease burden. The National Surgical Adjuvant Breast and Bowel Project (NSABP) proposed, in its inception, that there was a need to evaluate medicines that were potentially capable of altering, or even preventing, the initiation or promotion of non–clinically detectable cancers. ¹